153 results about "Depressed - symptom" patented technology

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The invention discloses application of a combination of probiotics GOLDGUT-M520 and GOLDGUT-LR99 in preparation of a product for relieving depression, and belongs to the technical field of biological medicines. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

To provide an AI system capable of estimating severity of dementia and / or depression in a subject on the basis of information obtained outside a hospital.SOLUTION: A method of creating teacher data for an AI system for estimating severity of dementia and / or depression is provided. Information to be used as teacher data for the AI system can be acquired from a site where a user receives prescribed drugs or from an application on a mobile terminal used by the user. The teacher data at least includes a face picture of the user, and a prescription, instruction, or information that enables estimation of dementia and / or depression in the user.SELECTED DRAWING: Figure 1

The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

The invention discloses a related product of FT3 in depression risk assessment and application, and relates to the field of depression diagnosis. The marker provided by the invention comprises FT3 and shows a remarkable technical effect in the aspect of predicting depression, high-precision early recognition and risk prediction of depression are realized, a key window and an objective basis are provided for early active intervention and whole-course management of diseases, and the accuracy and reliability of screening and diagnosis are greatly improved. Meanwhile, the marker has excellent universality, is suitable for wide population screening, and lays a technical foundation for low-cost and high-efficiency large-scale depression screening. In conclusion, a brand new technical means is provided for effective diagnosis and risk early warning of depression, and the industrial application prospect is wide.

The present invention relates to a method for the differential diagnosis of bipolar versus unipolar disorder in a human patient during a depressive phase from a biological sample of the patient, comprising determining the relative proportions of RNA editing variants of at least the A-to-I-edited RNA ZNF267 gene. The present invention also relates to a method for monitoring the treatment of a depressed patient exhibiting bipolar or unipolar disorder. Finally, the present invention provides a kit for the differential diagnosis of bipolar versus unipolar disorder in a patient during a depressive phase.

This invention belongs to the fields of pharmaceutical biotechnology and clinical medicine, specifically relating to a peripheral blood phosphatidylethanolamine biomarker for the objective diagnosis of depression, and particularly to the application of phosphatidylethanolamine (PE) (18:1 / 18:3) in the diagnosis and risk assessment of depression. This invention provides an objective diagnostic method based on peripheral blood, overcoming the inherent subjectivity of traditional psychiatric diagnoses, and can be used for the auxiliary diagnosis, early screening, and risk assessment of depression.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The application relates to a reagent combination for detecting depression, a manufacturing method, a detection system and application thereof, and belongs to the technical field of instrument detection. The reagent combination for detecting depression comprises a calibrator, a quality control sample and an extraction solution of a to-be-detected compound serving as a biomarker; wherein the to-be-detected compound is at least three kinds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine and norepinephrine. The reagent combination for detecting depression and the detection system can significantly improve the accuracy of diagnosis, are convenient to detect, have good repeatability of detection data, are high in specificity, and are accurate in clinical diagnosis results.

FIELD: psychiatry; narcology.SUBSTANCE: used to stabilize remission of alcohol dependence in patients with comorbid depression. After the withdrawal state with alcohol dependence syndrome and comorbid depressive disorder has been relieved, the patient takes agomelatine orally at a dosage of 25 mg once a day daily for 12 weeks.EFFECT: method is accessible and allows for stabilizing remission in patients with alcohol dependence syndrome and depressive disorder.1 cl

The invention discloses application of plasma neuron-derived exosomes in depression diagnosis, the neuron-derived exosomes are extracted from plasma to detect NDEVs in serum and detect the USP11 level, and the USP11 level in the NDEVs of a depression patient is found to be significantly higher than that in a healthy control, so that the USP11 level in the NDEVs in the serum can reflect the biological state of an intracranial nerve cell state. The detection specificity and sensitivity can be remarkably improved in the diagnosis of depression, and the method has very high clinical application value.

Embodiments directed to a computer-implemented diagnostic system and method to determine various diagnoses for different users, as well as symptom severity and onset of conditions associated with such diagnoses are described. In one example, a computer-implemented method of diagnosing health conditions for users includes identifying a defined linguistic pattern in digital biomarker data of a user. The method further includes prompting the user to perform a defined screening test based at least in part on identifying the defined linguistic pattern. The method further includes monitoring linguistic performance of the user while the user performs the defined screening test. The method further includes determining a diagnosis for the user based at least in part on the defined linguistic pattern, the linguistic performance, and a test result for the user from the defined screening test.

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

The application discloses an application of NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression, and belongs to the technical field of medicines. Specifically, the application relates to an application of a compound NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression. The CAS registration number of the compound NOD2 antagonist 1 is 2411441-54-6. The application discloses a brand-new medicinal use of NOD2 antagonist 1, that is, the compound can be used for preparing a medicine for preventing or treating depression. Animal experiment results show that after intervention of NOD2 antagonist 1, the sucrose preference behavior of a depression model mouse is obviously improved, and depression-related emotional disorder performance is also obviously relieved. Based on the pharmacodynamic verification results, the technical scheme provided by the application has good clinical transformation and popularization and application prospects.

The invention discloses a novel application of Vanin-1 protein as a depression diagnosis biomarker as well as a related mechanism and application of the Vanin-1 protein, and particularly discloses that liver Vanin-1 deficiency is a core mechanism of depression attack, and a key function of the liver Vanin-1 deficiency is verified through functional experiments. Meanwhile, the invention discloses that the Vanin-1 protein in blood can be used as a molecular marker for diagnosing depression, and the reduction of the content of the Vanin-1 protein indicates the risk of depression.

The present application relates to the field of biological science, and particularly relates to the use of a SCN11A protein detection reagent in the preparation of a depression screening and depression treatment effect evaluation kit. It is found for the first time that the expression level of SCN11A protein in the peripheral blood serum of a depression patient is significantly higher than that of a healthy subject. The reagent for detecting SCN11A protein is used in the preparation of a depression screening kit, so that effective screening of depression and evaluation of the treatment effect of depression can be realized.

The present application relates to the use of clemastine in the manufacture of a medicament for the treatment of depression. The present application first discovered that clemastine has the efficacy of treating depression, and clemastine can effectively alleviate the depression-like phenotype of mice induced by chronic unpredictable mild stimulation or lipopolysaccharide by promoting oligodendrocyte myelination.

To provide an AI system capable of estimating severity of dementia and / or depression in a subject on the basis of information obtained outside a hospital.SOLUTION: A method of creating teacher data for an AI system for estimating severity of dementia and / or depression is provided. Information to be used as teacher data for the AI system can be acquired from a site where a user receives prescribed drugs or from an application on a mobile terminal used by the user. The teacher data at least includes a face picture of the user, and a prescription, instruction, or information that enables estimation of dementia and / or depression in the user.SELECTED DRAWING: Figure 1

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The application relates to the technical field of medicines, in particular to application of glycyrrhiza chalcone A in preparation of medicines for treating depression. The application experiment shows that the glycyrrhiza chalcone A can significantly improve the CUMS-induced depression-like behavior of mice, reduce the hippocampal neuron damage, inhibit the neuroinflammatory reaction, and restore the 5-HT level, and the anti-depression mechanism may be closely related to multiple mechanisms such as down-regulation of MAPK / JNK path activity, inhibition of inflammatory factor expression and neurotransmitter regulation.

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

The invention discloses a method and device for predicting the curative effect of depression with insomnia and a storage medium, and the method comprises the steps: finding a core medication strategy through the drug proportion, association strength and drug compliance, and constructing a model for predicting the curative effect of a core treatment scheme on a patient with depression with insomnia in a real diagnosis and treatment environment; and high-quality evidence is provided for personalized treatment of patients with depression. The method comprises the following steps: acquiring a medical record data set of a patient, and performing dimensionality reduction fitting on medical record data in the medical record data set to obtain a low-dimensional treatment scheme set; after calculating the similarity of the low-dimensional treatment schemes, dividing the low-dimensional treatment schemes into a plurality of groups of treatment schemes according to preset conditions; multiple groups of treatment schemes are verified through prospective follow-up visit, the relevance between medication modes of different follow-up visit points and insomnia symptoms or sleep quality is analyzed, and a core treatment scheme set is obtained; constructing a curative effect prediction model according to the core treatment scheme set and the time for controlling the illness state of the patient; and inputting medical record data of a to-be-detected patient to the curative effect prediction model to obtain a recommended treatment scheme.

This invention relates to the field of microbial pharmaceutical technology, specifically disclosing the application of *Blautia Obeum* in the preparation of drugs for the prevention and treatment of depression, representing a novel use of probiotics for antidepressant purposes. This invention is the first to apply *Blautia Obeum* to the prevention and treatment of depression. This strain can be prepared in various forms, including live bacterial preparations, inactivated bacterial cells, bacterial lysates, metabolites, or bacterial extracts, combined with pharmaceutically acceptable excipients to formulate various oral microecological preparations, including conventional dosage forms such as tablets, capsules, enteric-coated preparations, and oral liquids. The drugs can effectively improve core clinical symptoms of depression, such as low mood, loss of interest, sleep disorders, anxiety, and irritability, by regulating intestinal flora homeostasis, repairing intestinal barrier function, and modulating the brain-gut axis signaling pathway. It is suitable for the prevention and treatment of various types of depression, including major depressive disorder, postpartum depression, geriatric depression, and chronic stress-induced depression. The strain used in this invention is safe and highly compatible, and the preparation is convenient to administer, providing a novel microecological intervention scheme for the clinical prevention and treatment of depression, overcoming some limitations of existing antidepressant methods, and possessing good prospects for pharmaceutical development.

The application discloses a negative ion metabolic marker related to adolescent depression, a product and an application. The metabolic marker comprises any one or several of the following: Homogentisic acid, Aurantio-obtusin, 3-o-acetyl-16alpha-hydroxytrametenolic acid, Leoidin and Kynurenic acid. The application provides a kit comprising detection reagents for detecting the negative ion metabolic marker. The application provides a computer program product related to adolescent depression. The product provided by the application has good feasibility and accuracy, can effectively evaluate the risk of adolescent depression, and provides a new tool for clinical diagnosis.

Described herein are methods for treating depression and / or preventing a relapse in depression in a patient, comprising: administering to the patient a first dose comprising 9-[4- (Cyclohexyloxy)phenyi]-7-methyl-3,4-dihydropyrazino[2, 1-c][l,2,4]thiadiazine 2,2-dioxide ("COMPOUND A" or "CMPD A") or a salt thereof; and administering to the patient at least one daily maintenance dose comprising COMPOUND A or a salt thereof, wherein the at least one daily maintenance dose is less than the first dose.

Objective discrimination of a disease label of a depressive symptom with respect to an active state of a brain is achieved. One means for solving the problems of the present invention is to provide a discriminating device for assisting in determination of whether a subject has a depressive symptom. The discriminating device includes a storage device for storing information for identifying a classifier generated by classifier generation processing based on a signal obtained by using a brain activity detecting apparatus to measure, in advance and time-sequentially, a signal indicating a brain activity of a plurality of predetermined regions of each brain of a plurality of participants in a resting state, the plurality of participants including healthy individuals and patients with depression. The classifier is generated so as to discriminate a disease label of a depressive symptom based on a weighted sum of a plurality of functional connectivities selected by feature selection as being relevant to the disease label of the depressive symptom through machine learning from among functional connectivities of the plurality of predetermined regions. The discriminating device further includes a processor configured to execute discriminating processing of generating a classification result for the depressive symptom of the subject by using the classifier.

The present invention relates to the use of agomelatine (or a prodrug or salt thereof) in the treatment of severe depression or bipolar affective disorder, comprising selecting a patient who will benefit most from agomelatine.

1. Name of the design product: depression evaluation robot. 2. Use of the design product: for assisting clinicians in diagnosing depression. 3. Design points of the design product: in shape. 4. Picture or photograph best indicating the design points: perspective view.